Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.

MLA

Campbell, Brittany B., et al. “Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.” Cancer Discovery, vol. 11, no. 6, June 2021, pp. 1454–67. EBSCOhost, https://doi.org/10.1158/2159-8290.CD-20-1050.

APA

Campbell, B. B., Galati, M. A., Stone, S. C., Riemenschneider, A. N., Edwards, M., Sudhaman, S., Siddaway, R., Komosa, M., Nunes, N. M., Nobre, L., Morrissy, A. S., Zatzman, M., Zapotocky, M., Joksimovic, L., Kalimuthu, S. N., Samuel, D., Mason, G., Bouffet, E., Morgenstern, D. A., … Tabori, U. (2021). Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discovery, 11(6), 1454–1467. https://doi.org/10.1158/2159-8290.CD-20-1050

Chicago

Campbell, Brittany B, Melissa A Galati, Simone C Stone, Alexandra N Riemenschneider, Melissa Edwards, Sumedha Sudhaman, Robert Siddaway, et al. 2021. “Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.” Cancer Discovery 11 (6): 1454–67. doi:10.1158/2159-8290.CD-20-1050.